| Literature DB >> 20109593 |
Marie-Josee J Mangen1, Yvonne T H P van Duynhoven, Harry Vennema, Wilfrid van Pelt, Arie H Havelaar, Hester E de Melker.
Abstract
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20109593 DOI： 10.1016/j.vaccine.2010.01.014
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641